Purpose of Technology

Recombinant human bone morphogenetic protein (rhBMP) serves as an alternative or adjunct to autologous bone grafts (autografts). It is used in spinal fusion surgery for degenerative disease to promote the bone growth that results in fusion.

Questions addressed in this report include:

• Are rhBMP-2 and rhBMP-7 effective in promoting fusion or improving symptoms and function and how do these products compare with autografts or other alternatives?
• Are these products safe?
• Have definitive patient selection criteria been established for the use of these products in spinal fusion?

These questions provide a framework for review and synthesis of the best available evidence, which is presented in this report, along with the Hayes Ratings for the technology. This report also provides background information about the condition being treated, a description of the technology, and the context for development of the technology. Other key elements addressed in the report include the regulatory status; applicable Medicare and commercial payer coverage policies; relevant ICD-9 and ICD-10 diagnosis codes; cost and cost effectiveness; credentialing; hospital length of stay; need for large case management; and ongoing and future clinical trials of the technology.

Posted in Directory Reports
This entry was posted on Thursday, August 25th, 2011 at 8:00 am.